NPTN, NeoPhotonics Corporation

** NPTN reported that, based on preliminary financial estimates, NPTN expects revenue for its second quarter ended June 30, 2012, to be above its previously stated revenue outlook of $55.0 to $61.0 million.

The revenue estimate is preliminary and subject to adjustment; however, in the absence of material adjustment, second quarter revenue would set a new revenue record for NPTN.

According to NPTN, the acceleration of revenue growth in the second quarter was driven primarily by increased demand in a range of products for high speed coherent networks, high speed client applications and access networks.

NPTN is a leading designer and manufacturer of photonic integrated circuit, or PIC, based modules and subsystems for bandwidth-intensive, high-speed communications networks.

More about NPTN at www.neophotonics.com.

*************

NYMX, Nymox Pharmaceutical Corp.

** NYMX provided an update on its Phase 3 NX02-0020 repeat injection U.S. study for NX-1207, NYMX's investigational-drug for benign prostatic hyperplasia (BPH).

The recent Safety Monitoring Committee meeting was favorable and indicated no significant safety concerns for the trial to date.

Patient recruitment and trial activities for this U.S. Phase 3 Study are nearing completion at well-known urology investigative sites throughout the U.S.

NYMX's NX-1207 has been shown to improve the signs and symptoms of BPH, producing improvements which in previous studies have reached statistical significance compared to double-blinded placebo and study controls.

A single administration of NX-1207 2.5 mg has produced on average improvements in the standardized BPH symptom score (8-10 points at 90 days) that were approximately double that reported for currently approved BPH drugs (3-5 points). The drug is administered by a urologist in an office setting and involves little or no pain or discomfort. NX-1207 has not been found to have the-sexual, blood pressure, or other side effects of the approved-drugs. Follow-up studies have shown clinical efficacy effects in many men lasting up to 71/2 years after a single treatment.

Benign prostatic hyperplasia (BPH) is one of the most commonly diagnosed conditions in the male population. The condition can seriously impact the health and quality of life of middle aged and older men. It is estimated that 50% of men in their 50s have pathological signs of prostatic hyperplasia and a high proportion of men as they age suffer from moderate to severe urinary problems and symptoms associated with BPH.

NYMX specializes in the research and development of novel drugs and diagnostic products for the aging population.

More about NYMX at www.nymox.com

*************

MSFT, Microsoft Corp.

** MSFT and Aluratek, Inc. reported that they have signed a patent agreement that provides broad coverage under MSFT's patent portfolio for Aluratek's eReaders and tablets running the Android or Chrome Platform.

Although the contents of the agreement have not been disclosed, the parties indicate that MSFT will receive royalties from Aluratek under the agreement.

MSFT also reported that it has signed a patent agreement with Coby Electronics Corporation that provides broad coverage under MSFT's patent portfolio for Coby's products running the Android or Chrome Platform.

Although the contents of the agreement have not been disclosed, the parties indicate that MSFT will receive royalties from Coby under the agreement.

MSFT is the worldwide leader in software, services and solutions that help people and businesses realize their full potential.

More about MSFT at www.microsoft.com

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE) advertises for a particular client, Crown Equity Holdings Inc. (CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE), if paid in stock, can and may sell those securities during the advertising period.